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Background: Significance and clinical utility of multiple virus detection by multiplex real-time polymerase chain
reaction (rtPCR) in respiratory tract infection remain unclear.
Methods: This retrospective cohort study analyzed how virus detection affected clinical management. During a 27-
month period, clinical and laboratory information was collected from all children and adults in two Swiss tertiary centres
whose respiratory samples were tested for respiratory viruses with a 16-plex rtPCR test.
Results: Pathogens were identified in 140 of 254 patients (55%); of those patients, there was ≥1 virus in 91 (65%), ≥ 1
bacterium in 53 (38%), and ≥1 virus and bacterium in 11 (8%). Of 80 patients with viral infection, 59 (74%) received
antibiotics. Virus detection was associated with discontinuation of antibiotics in 2 of 20 adults (10%) and 6 of 14 children
(43%). Overall 12 adults (34%) and 18 children (67%) were managed correctly without antibiotics after virus
detection (p = 0.01). When taking biomarkers, radiologic presentations, and antibiotic pre-treatment into account,
the impact of rtPCR and appropriateness of therapy for clinically viral infections increased to 100% in children and
62% in adults.
Conclusions: A substantial reduction of unnecessary antibiotic prescriptions seems possible. Appropriate application
of rtPCR results in respiratory tract infections should be encouraged.
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Establishing the etiology of respiratory tract infections
(RTI) is often difficult due to the lack of a diagnostic
gold standard and the inability to detect the causative
pathogen. A large proportion of RTI is believed to be
caused by respiratory viruses [1–6]. With widespread
availability of molecular methods such as multiplex real-
time polymerase chain reaction (rtPCR), clinical work-
flow has changed dramatically and the sensitivity of viral
diagnostics has increased remarkably compared to con-
ventional methods [3, 7–13]. However, the significance
of virus detection remains unclear as the presence of a
virus does not prove causality. Many respiratory viruses
can be carried by asymptomatic children [4, 6, 14] and* Correspondence: Werner.Albrich@kssg.ch
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Viral infection was reported previously to predispose to
bacterial super-infection and concerns about possible
bacterial co-infection remain [3, 7–13, 16–19]. Ruling
out a bacterial infection with traditional microbiological
techniques is frequently impossible [1, 5]. The predictive
value of clinical signs to differentiate between viral and
bacterial infection is also low [13, 17, 20–22]. On these
grounds, clinical management of patients after respira-
tory virus diagnosis is controversial and surprisingly
poorly studied. Overall, extensive yet often unnecessary
use of antibiotics in RTI is common [1, 5, 6]. This adult
and pediatric retrospective cohort study analyzed
whether identification of a virus by multiplex rtPCR was
associated with changes in the antibiotic treatment.le is distributed under the terms of the Creative Commons Attribution 4.0
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Study design and population
This was a retrospective cohort study of all pediatric and
adult in- and outpatients in whom a 16-plex rtPCR assay
for respiratory viruses was performed for upper and lower
RTI, from either the Kantonsspital St. Gallen or Children’s
hospital of Eastern Switzerland. Both hospitals are
tertiary-care Swiss teaching hospitals with active infectious
diseases consult services and easily accessible web-based
local guidelines (www.guidelines.ch) for the treatment of
community-acquired or hospital-acquired pneumonia.
The guidelines are strongly recommended for use but not
strictly reinforced, and include use of rtPCR as optional
diagnostic in hospitalized patients, particularly with im-
mune suppression. The study period was from September
2012 (when this assay was introduced) to November 2014.
The documented application dates of anti-infective medi-
cation were matched with the date of rtPCR analysis in
order to determine whether treatment was changed in re-
sponse to rtPCR results. The main outcome of interest
was whether antibiotic therapy was modified according to
results of multiplex rtPCR. Secondary outcomes were
prevalence and distribution of positive results of rtPCR,
complications, length of stay (LOS), and antibiotic therapy
depending on identified pathogens.
Data collection
To identify patients, the database of the Centre for Labora-
tory Medicine was searched. Medical records were retro-
spectively analyzed to obtain basic demographic, clinical,
laboratory and radiological parameters and data on clinical
management. All chest radiographs (CXR) and computed
tomographies (CT) for adults and children were reviewed
by a pulmonologist and a pediatrician, respectively.
Clinical definitions
rtPCR results were available within 24 hours after test-
ing. The application dates of anti-infective medication as
documented in the medical records were correlated with
the day of, or the day after, rtPCR analysis in order to
define whether treatment initiation or discontinuation
was associated with the results of viral testing.
The identified pathogens were retrospectively determined
as relevant by an infectious disease specialist who inte-
grated all available information. Etiologies were divided in
four mutually exclusive groups: (i) bacterial (≥1 bacteria);
(ii) viral (≥1 respiratory viruses); (iii) mixed (≥1 bacteria
and ≥1 respiratory viruses); or (iv) no pathogen (includ-
ing fungi, non-respiratory virus, bacterial contaminant
including coagulase-negative staphylococci, propioni-
bacterium, corynebacterium, colonizing oral and re-
spiratory flora). For some children, rapid detection tests
(Alere BinaxNOW Influenza A&B, Quidel QuickVue
RSV Test) for respiratory syncytial virus (RSV) andinfluenza A/B virus were available. These results were
additionally considered in forming the different groups.
For each patient, changes of antibiotic management,
i.e. either starting or stopping antibiotics, were deter-
mined. All other situations were defined as no change.
Management was considered correct for viral infec-
tions if there was no antibiotic treatment before and
after rtPCR or antibiotics were stopped after positive
rtPCR results became available; for bacterial or mixed
infections, if antibiotics were given before and after
rtPCR or were started after a negative rtPCR result. Pa-
tients with an indication other than RTI for antibiotic
therapy were excluded. For patients with febrile neutro-
penia without a specific focus, the antibiotic indication
was defined as “other” because antibiotics would usually
not be stopped despite a viral detection. If a patient
underwent repeated testing for respiratory viruses within
3 weeks, only the first positive result was counted. If the
time interval was longer or the detected viruses di-
verged, a different episode was presumed and analyzed
separately [23].
To reflect clinical decision making in real-life situations,
sub-analyses were performed. Cases without detection of
bacteria (i.e. patients with viral etiology or with no patho-
gen) were evaluated as clinically bacterial if they fulfilled
one of the following criteria: unilobar or multilobar
pulmonary infiltrate on CT or CXR; C-reactive pro-
tein (CRP) >100 mg/l; procalcitonin (PCT) >0.25 μg/l;
antibiotic therapy before rtPCR and with indeterminate
biomarkers (CRP >100 mg/l and PCT ≤0.25 μg/l or CRP
51–100 mg/l and PCT not available). These criteria were
adapted from earlier publications [17, 21] regarding the
diagnosis of bacterial lower RTI.
The subgroup of patients with a viral etiology who had
no clinically bacterial infection was considered to have a
clinically viral infection. Children (<18 years) and adults
(≥18 years) were analyzed separately. Sepsis was defined
according to standard criteria at the time [24]. Systemic in-
flammatory response syndrome (SIRS) criteria for children
were defined as age-specific [25].
For the imaging, if patients had interstitial infiltrates or
ground glass opacities in the absence of unilobar or multi-
lobar infiltrates, only therapy against “atypical” pathogens
(macrolide, quinolone, tetracycline; but not antibiotics for
coverage of “typical” bacterial pathogens) was considered
appropriate. If both CXR and CT were available, only CT
readings were used for further analyses. An infiltrate was
required for the diagnosis of pneumonia but no radiog-
raphy was needed to diagnose a RTI in general.
Laboratory procedures
The multiplex rtPCR was performed according to the
manufacturer’s instruction (Seegene, Korea). The Any-
plex™ II RV16 detection kit (Seegene, Korea) detects the
Table 1 Baseline characteristics for adult patients
Missing Total Virala Any virusb Otherc p-valued





Age, mean years ± SD
(range)
55.9 ± 16.1 (18–88) 53.6 ± 16.1 (18–83) 53.9 ± 15.9 (18–83) 56.6 ± 16.1 (18–88) 0.93 0.30
Female sex, n (%) 76 (41.8) 14 (35.0) 19 (41.3) 62 (43.7) 0.55 0.33
Outpatients, n (%) 20 (11.0) 5 (12.5) 5 (10.9) 15 (10.6) 1.00 0.92
Comorbidities, n (%)
Asthma 13 (7.1) 2 (5.0) 4 (8.7) 11 (7.7) 0.81 0.85
COPD 27 (10.6) 5 (12.5) 7 (15.2) 22 (15.5) 0.72 0.64
Other chronic lung diseasee 26 (14.3) 2 (5.0) 2 (4.3) 24 (16.9) 1.00 0.06
Solid cancerf 25 (13.7) 3 (7.5) 3 (6.5) 22 (15.5) 1.00 0.20
Hematologic malignancy 38 (20.9) 13 (32.5) 15 (32.6) 25 (17.6) 0.99 0.04
Organ transplantation 13 (7.1) 3 (7.5) 3 (6.5) 10 (7.0) 1.00 1.00
Neutropenia 20 (11.0) 9 (22.5) 9 (19.6) 11 (7.7) 0.74 0.03
HIV infection 6 (3.3) 1 (2.5) 2 (4.3) 5 (3.5) 1.00 1.00
Diabetes mellitus 27 (14.8) 6 (15.0) 7 (15.2) 21 (14.8) 0.98 0.97
Collagen vascular disease/
Vasculitis
33 (18.1) 4 (10.0) 5 (10.9) 29 (20.4) 1.00 0.13
Systemic steroids 49 (26.9) 11 (27.5) 14 (30.4) 38 (26.8) 0.77 0.93
Other Immunosuppressiong 21 (11.5) 5 (12.5) 6 (13.0) 16 (11.3) 0.94 1.00
Chronic renal failure 45 (24.7) 11 (27.5) 13 (28.3) 34 (23.9) 0.94 0.65
Clinical findings
Systolic blood pressure,
mmHg, mean ± SD (range)
9 125 ± 24 (63–207) 129 ± 27 (63–207) 128 ± 28 (63–207) 123 ± 22 (67–197) 0.87 0.17
Heart rate, beats/min,
mean ± SD (range)
8 94 ± 20 (51–155) 91 ± 19 (51–150) 94 ± 19 (51–150) 94 ± 20 (56–155) 0.47 0.40
Respiratory rate, breaths/min,
mean ± SD (range)
130 26 ± 9 (10–60) 23 ± 8 (12–36) 27 ± 13 (12–60) 27 ± 10 (10–60) 0.39 0.23
Body temperature, °C,
mean ± SD (range)
20 37.6 ± 1.0 (35.4–42.0) 37.5 ± 0.9 (35.6–39.6) 37.5 ± 0.9 (35.6–39.6) 37.6 ± 1.0 (35.4–42.0) 1.00 0.59
Laboratory findingsh, mean ± SD (range)
C-reactive protein
(maximum), mg/l
13 151 ± 127 (1–500) 159 ± 148 (1–500) 166 ± 152 (1–500) 148 ± 121 (1–499) 0.83 0.64
White blood cells
(maximum), G/l
11 11.5 ± 10.2 (0.0–97.0) 12.2 ± 16.8 (1.8–97.0) 12.6 ± 16.3 (1.8–97.0) 11.3 ± 7.3 (0.0–41.1) 0.91 0.75
Platelets (minimum), G/l 11 202 ± 128 (4–713) 159 ± 117 (5–513) 165 ± 117 (5–513) 215 ± 129 (4–713) 0.82 0.02
Discharge diagnosis, n (%)
Bronchitis 22 (12.1) 7 (17.5) 7 (15.2) 15 (10.6) 0.78 0.36
Acute exacerbation of COPD 5 (2.7) 1 (2.5) 1 (2.2) 4 (2.8) 1.00 1.00
Upper respiratory tract
infection
8 (4.4) 4 (10.0) 4 (8.7) 4 (2.8) 1.00 0.14
Respiratory tract infection,
unspecified
7 (3.8) 2 (5.0) 4 (8.7) 5 (3.5) 0.81 0.96
Community-acquired
pneumonia
65 (35.7) 21 (52.5) 25 (54.3) 44 (31.0) 0.86 0.01
Hospital-acquired pneumonia 12 (6.6) 0 (0.0) 0 (0.0) 12 (8.5) n/a 0.09
Mayer et al. Pneumonia  (2017) 9:4 Page 3 of 16
Table 1 Baseline characteristics for adult patients (Continued)
Aspiration pneumonia 1 (0.5) 0 (0.0) 0 (0.0) 1 (0.7) n/a 1.00
Tuberculosis 3 (1.6) 0 (0.0) 0 (0.0) 3 (2.1) n/a 0.95
Otheri 59 (32.4) 5 (12.5) 5 (10.9) 54 (38.0) 1.00 0.002
°C, degree Celsius, COPD chronic obstructive pulmonary disease, HIV human immunodeficiency virus, n number, SD standard deviation
aCases in which only one or more respiratory viruses were detected
bCases in which one or more respiratory viruses were detected (as single or mixed infection)
cIncludes bacterial etiology, mixed etiology, no pathogen
dFor continuous variables, 2-sample independent t-test was used. For categorical variables, Mantel-Haenszel chi square or Fisher exact test were used
eOther chronic lung diseases, e.g. cystic fibrosis, pulmonary sarcoidosis, pulmonary hypertension
fAll solid tumors including bronchial carcinoma
gPatients with one of the following conditions: primary or secondary antibody deficiency, congenital immunodeficiency, immunosuppressive therapy other than
steroids, severe malnutrition with cachexia
hHighest/lowest value within a time period of 3 days before and 3 days after date of rtPCR
iOther infections (n = 10); neoplastic diseases (n =6); collagen vascular; other rheumatologic or autoimmune (n = 14); sarcoidosis (n = 3); non-infectious non-
neoplastic pulmonary diseases (n = 23); cardiovascular diseases (n = 3)
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enza B virus, parainfluenza virus 1, parainfluenza virus 2,
parainfluenza virus 3, parainfluenza virus 4, rhinovirus
A/B/C, RSV A, RSV B, bocavirus 1/2/3/4, human metap-
neumovirus, coronavirus 229E, coronavirus NL63, cor-
onavirus OC43, and enterovirus. Specimens that arrived
before mid-morning from Monday to Friday were proc-
essed daily and results were provided by mid-afternoon.
Specimens that arrived afterwards were processed on the
following workday and reported by mid-afternoon. Dates
of specimen collection and testing were available, but
not date and time of reporting of results. For CRP, white
blood cell count (WBC) and platelets, the most patho-
logic values within 3 days before and after rtPCR results
were documented.
Statistical analyses
Quantitative variables are described as means ± standard
deviations or median and interquartile range (IQR), as
appropriate. Qualitative variables are presented as abso-
lute counts and relative percentages. χ2-test or Fisher’s
exact test were used to compare proportions, as ap-
propriate. For continuous variables, the 2-sample in-
dependent t-test or the Mann-Whitney-U-test were
used. P-values ≤0.05 (2-sided) were considered statis-
tically significant. Multivariate logistic regression was
used to examine whether different predictors were as-
sociated with virus detection. Variables with a p-value
≤0.05 in the univariate logistic regression were in-
cluded. SPSS version 20.0 for Windows software,
OpenEpi (www.openepi.com) and Microsoft Excel
2010 were used for statistical analyses.
Results
rtPCR for respiratory viruses was performed on 328 re-
spiratory specimens, of which 74 samples were excluded
due to insufficient clinical information or repeated test-
ing of separate specimens for respiratory viruses in the
same patient within 3 weeks. Data on 254 patients wereanalyzed, including 11 sputa, 47 nasopharyngeal swabs,
63 nasopharyngeal aspirates, 123 bronchoalveolar la-
vages, 9 tracheal aspirates and 1 pleural effusion.
Clinical characteristics
Baseline characteristics are presented in Tables 1, 2 and
3. One hundred and seven patients (42%) were female,
and 72 were children (28%). Mean age in the group with
viral infections was lower than in the remaining patients
(29 vs. 47 years; p < 0.001) but the difference was not
significant if children and adults were analyzed separ-
ately (children 4.3 vs. 5.7 years; p = 0.28; adults 53.6 vs.
56.6 years; p = 0.31). There were more patients with neu-
tropenia, hematological malignancy or collagen vascular
disease/vasculitis in the viral group (p < 0.001; p = 0.04;
p = 0.01). Diagnosis of bronchitis and upper RTI were
more common in the viral group (p = 0.02; p = 0.004).
Pathogen identification
Any pathogen was identified in 140 patients (55%), in 89
of 182 adults (49%) and in 51 of 72 children (71%).
Among these patients, one or more respiratory virus was
detected in 91 (65%), one or more bacteria in 53 (38%)
and a mixed viral-bacterial infection in 11 (8%) patients.
45 of 72 children (63%) were infected with one or more
respiratory viruses. Compared to children, viral detection
in adults was less frequent (25%, n = 46; p < 0.001). A
single pathogen was identified in 99 patients (39%); mul-
tiple pathogens were detected in 41 patients (16%). Dis-
tribution of detected pathogens and the differences
between children and adults are shown in Table 4, and
Figs. 1, 2a and b.
Antibiotic therapy
Of the 254 patients in the cohort, 61 (24%) received anti-
biotics before hospitalization, and 149 (59%) of all in- and
outpatients received antibiotics at the time of rtPCR test-
ing. Of 80 patients with a viral etiology, 59 (74%) received
antibiotics at any time point, 28 of 40 children (70%) and
Table 2 Baseline characteristics for pediatric patients
Missing Total Virala Any virusb Otherc p-valued





Age, mean years ± SD
(range)
4.9 ± 5.7 (0–17) 4.3 ± 5.4 (0–16) 4.7 ± 5.5 (0–16) 5.7 ± 6.0 (0–17) 0.74 0.30
Female sex, n (%) 31 (43.1) 14 (35.0) 18 (40.0) 17 (53.1) 0.64 0.13
Outpatients, n (%) 3 (4.2) 2 (5.0) 2 (4.4) 1 (3.1) 1.00 1.00
Comorbidities, n (%)
Asthma 1 (1.4) 1 (2.5) 1 (2.2) 0 (0.0) 1.00 1.00
Other chronic lung diseasee 13 (18.1) 7 (17.5) 8 (17.8) 6 (18.8) 0.97 0.89
Solid cancerf 1 (1.4) 0 (0.0) 0 (0.0) 1 (3.1) n/a 0.89
Haematologic malignancy 10 (13.9) 8 (20.0) 9 (20.0) 2 (6.3) 1.00 0.18
Organ transplantation 1 (1.4) 1 (2.5) 1 (2.2) 0 (0.0) 1.00 1.00
Neutropenia 9 (12.5) 8 (20.0) 8 (17.8) 1 (3.1) 0.79 0.06
Systemic steroids 8 (11.1) 5 (12.5) 6 (13.3) 3 (9.4) 0.91 0.98
Other Immunosuppressiong 3 (4.2) 3 (7.5) 3 (6.7) 0 (0.0) 1.00 0.33
Clinical findings
Systolic blood pressure,
mmHg, mean ± SD (range)
29 100 ± 18 (59–140) 106 ± 15 (71–140) 105 ± 14 (71–140) 95 ± 18 (59–120) 0.82 0.04
Heart rate, beats/min,
mean ± SD (range)
3 136 ± 33 (60–234) 138 ± 32 (60–186) 134 ± 32 (60–186) 135 ± 35 (72–234) 0.58 0.71
Respiratory rate, breaths/min,
mean ± SD (range)
15 41 ± 20 (16–103) 41 ± 21 (18–103) 40 ± 21 (16–103) 40 ± 19 (16–88) 0.84 0.86
Body temperature, °C,
mean ± SD (range)
3 37.6 ± 1.1 (35.0–40.1) 37.5 ± 1.1 (35.0–39.5) 37.5 ± 1.1 (35.0–39.5) 37.7 ± 1.1 (35.1–40.1) 1.00 0.46
Laboratory findingsh, mean ± SD (range)
C-reactive protein
(maximum), mg/l
2 85 ± 141 (5–999) 62 ± 77 (5–291) 67 ± 81 (5–293) 113 ± 191 (7–999) 0.78 0.16
White blood cells
(maximum), G/l
2 16.0 ± 12.1 (0.2–63.1) 12.6 ± 10.0 (0.2–57.0) 13.6 ± 11.3 (0.2–57.0) 20.1 ± 13.3 (1.8–63.1) 0.68 0.01
Platelets (minimum), G/l 2 246 ± 144 (15–674) 257 ± 175 (15–674) 244 ± 169 (15–674) 234 ± 96 (16–488) 0.73 0.49
Discharge diagnosis, n (%)
Bronchitis 10 (13.9) 9 (22.5) 9 (20.0) 1 (3.1) 0.78 0.04
Upper respiratory tract
infection
14 (19.4) 9 (22.5) 10 (22.2) 5 (15.6) 0.98 0.47
Respiratory tract infection,
unspecified
4 (5.6) 4 (10.0) 4 (8.9) 0 (0.0) 1.00 0.18
Community-acquired
pneumonia
15 (20.8) 6 (15.0) 8 (17.8) 9 (28.1) 0.73 0.18
Hospital-acquired pneumonia 10 (13.9) 5 (12.5) 6 (13.3) 5 (15.6) 0.91 0.96
Aspiration pneumonia 2 (2.8) 1 (2.5) 2 (4.4) 1 (3.1) 1.00 1.00
Otheri 17 (23.6) 6 (15.0) 6 (13.3) 11 (34.4) 0.83 0.06
°C, degree Celsius, COPD chronic obstructive pulmonary disease, HIV human immunodeficiency virus, n number, SD standard deviation
aCases in which only one or more respiratory viruses were detected
bCases in which one or more respiratory viruses were detected (as single or mixed infection)
cIncludes bacterial etiology, mixed etiology, no pathogen
dFor continuous variables, 2-sample independent t-test was used. For categorical variables, Mantel-Haenszel chi square or Fisher exact test were used
eOther chronic lung diseases, e.g. cystic fibrosis, pulmonary sarcoidosis, pulmonary hypertension
fAll solid tumors including bronchial carcinoma
gPatients with one of the following conditions: primary or secondary antibody deficiency, congenital immunodeficiency, immunosuppressive therapy
other than steroids, severe malnutrition with cachexia
hHighest/lowest value within a time period of 3 days before and 3 days after date of rtPCR
iOther infections (n = 14); neoplastic diseases (n = 1); collagen vascular; other rheumatologic or autoimmune (n = 1); gastroesophageal diseases (n = 1)
Mayer et al. Pneumonia  (2017) 9:4 Page 5 of 16
Table 3 Baseline characteristics for all patients
Missing Total Virala Any virusb Otherc p-valued





Age, mean years ± SD (range) 41.5 ± 26.9 (0–88) 29.0 ± 27.5 (0–83) 29.6 ± 27.4 (0–83) 47.2 ± 24.7 (0–88) 0.89 <0.001
Female sex, n (%) 107 (42.1) 28 (35.0) 37 (40.7) 79 (45.4) 0.45 0.12
Children, n (%) 72 (28.3) 40 (50.0) 45 (49.5) 32 (18.4) 0.94 <0.001
Outpatients, n (%) 23 (9.1) 7 (8.8) 7 (7.7) 16 (9.2) 0.80 0.91
Comorbidities, n (%)
Asthma 14 (5.5) 3 (3.8) 5 (5.5) 11 (6.3) 0.87 0.61
COPD 27 (10.6) 5 (6.3) 7 (7.7) 22 (12.6) 0.71 0.13
Other chronic lung diseasee 39 (15.4) 9 (11.3) 10 (11.0) 30 (17.2) 0.96 0.22
Solid cancerf 26 (10.2) 3 (3.8) 3 (3.3) 23 (13.2) 1.00 0.02
Haematologic malignancy 48 (18.9) 21 (26.3) 24 (26.4) 27 (15.5) 0.99 0.04
Organ transplantation 14 (5.5) 4 (5.0) 4 (4.4) 10 (5.7) 1.00 1.00
Neutropenia 29 (11.4) 17 (21.3) 17 (18.7) 12 (6.9) 0.68 <0.001
HIV infection 6 (2.4) 1 (1.3) 2 (2.2) 5 (2.9) 1.00 0.77
Diabetes mellitus 27 (10.6) 6 (7.5) 7 (7.7) 21 (12.1) 0.96 0.28
Collagen vascular disease/Vasculitis 33 (13.0) 4 (5.0) 5 (5.5) 29 (16.7) 1.00 0.01
Systemic steroids 57 (22.4) 16 (20.0) 20 (22.0) 41 (23.6) 0.75 0.53
Other Immunosuppressiong 24 (9.4) 8 (10.0) 9 (9.9) 16 (9.2) 0.98 0.84
Chronic renal failure 45 (17.7) 11 (13.8) 13 (14.3) 34 (19.5) 0.92 0.26
Clinical findings
Systolic blood pressure,
mmHg, mean ± SD (range)
38 120 ± 25 (59–207) 121 ± 26 (63–207) 119 ± 26 (63–207) 119 ± 24 (59–197) 0.67 0.60
Heart rate, beats/min,
mean ± SD (range)
11 106 ± 31 (51–234) 114 ± 35 (51–186) 114 ± 33 (51–186) 102 ± 28 (56–234) 1.00 0.01
Respiratory rate, breaths/min,
mean ± SD (range)
145 34 ± 18 (10–103) 37 ± 21 (12–103) 37 ± 20 (12–103) 32 ± 15 (10–88) 1.00 0.17
Body temperature, °C,
mean ± SD (range)
23 37.6 ± 1.0 (35.0–42.0) 37.5 ± 1.0 (35.0–39.6) 37.5 ± 1.0 (35.0–39.6) 37.6 ± 1.0 (35.1–42.0) 1.00 0.48
Laboratory findingsh, mean ± SD (range)
C-reactive protein
(maximum), mg/l
15 132 ± 134 (1–999) 111 ± 127 (1–500) 117 ± 132 (1–500) 141 ± 137 (1–999) 0.77 0.11
White blood cells
(maximum), G/l
13 12.8 ± 11.0 (0.0–97.0) 12.4 ± 13.8 (0.2–97.0) 13.1 ± 14.0 (0.2–97.0) 13.1 ± 9.4 (0.0–63.1) 0.75 0.69
Platelets (minimum), G/l 13 215 ± 134 (4–713) 208 ± 156 (5–674) 204 ± 149 (5–674) 218 ± 123 (4–713) 0.87 0.62
Discharge diagnosis, n (%)
Bronchitis 32 (12.6) 16 (20.0) 16 (17.6) 16 (9.2) 0.69 0.02
Acute exacerbation of COPD 5 (2.0) 1 (1.3) 1 (1.1) 4 (2.3) 1.00 0.99
Upper respiratory tract
infection
22 (8.7) 13 (16.3) 14 (15.4) 9 (5.2) 0.88 0.004
Respiratory tract infection,
unspecified
11 (4.3) 6 (7.5) 8 (8.8) 5 (2.9) 0.76 0.18
Community-acquired
pneumonia
80 (31.5) 27 (33.8) 33 (36.3) 53 (30.5) 0.73 0.60
Hospital-acquired pneumonia 22 (8.7) 5 (6.3) 6 (6.6) 17 (9.8) 0.93 0.36
Aspiration pneumonia 3 (1.2) 1 (1.3) 2 (2.2) 2 (1.1) 1.00 1.00
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Table 3 Baseline characteristics for all patients (Continued)
Tuberculosis 3 (1.2) 0 (0.0) 0 (0.0) 3 (1.7) n/a 0.64
Otheri 76 (29.9) 11 (13.8) 11 (12.1) 65 (37.4) 0.75 <0.001
°C, degree Celsius, COPD chronic obstructive pulmonary disease, HIV human immunodeficiency virus, n number, SD standard deviation
aCases in which only one or more respiratory viruses were detected
bCases in which one or more respiratory viruses were detected (as single or mixed infection)
cIncludes bacterial etiology, mixed etiology, no pathogen
dFor continuous variables, 2-sample independent t-test was used. For categorical variables, Mantel-Haenszel chi square or Fisher exact test were used
eOther chronic lung diseases, e.g. cystic fibrosis, pulmonary sarcoidosis, pulmonary hypertension
fAll solid tumors including bronchial carcinoma
gPatients with one of the following conditions: primary or secondary antibody deficiency, congenital immunodeficiency, immunosuppressive therapy other than
steroids, severe malnutrition with cachexia
hHighest/lowest value within a time period of 3 days before and 3 days after date of rtPCR
iOther infections (n = 24); neoplastic diseases (n = 7); collagen vascular; other rheumatologic or autoimmune (n = 15); sarcoidosis (n = 3); non-infectious non-
neoplastic pulmonary diseases (n = 23); cardiovascular diseases (n = 3); gastroesophageal diseases (n = 1)
Table 4 Relevant pathogens identified from respiratory specimens
Total (n = 254) Adults (n = 182) Children (n = 72)
Bacteria, n (%) 66 (26.0) 54 (29.7) 12 (16.7)
Haemophilus influenzae 12 (4.7) 11 (6.0) 1 (1.4)
Klebsiella pneumoniae 8 (3.1) 6 (3.3) 2 (2.8)
Staphylococcus aureus 4 (1.6) 1 (0.5) 3 (4.2)
Escherichia coli 4 (1.6) 3 (1.6) 1 (1.4)
Pseudomonas aeruginosa 4 (1.6) 4 (2.2) 0 (0.0)
Streptococcus pneumoniae 3 (1.2) 2 (1.1) 1 (1.4)
Streptococcus pyogenes 3 (1.2) 2 (1.1) 1 (1.4)
Legionella pneumophila 3 (1.2) 3 (1.6) 0 (0.0)
Mycobacterium tuberculosis 3 (1.2) 3 (1.6) 0 (0.0)
Mycoplasma pneumoniae 1 (0.4) 0 (0.0) 1 (1.4)
Other bacteria 21 (8.3) 19 (10.4) 2 (2.8)
Viruses, n (%) 119 (46.9) 54 (29.7) 65 (90.3)
Rhinovirus A/B/C 33 (13.0) 16 (8.8) 17 (23.6)
Influenza A virus 17 (6.7) 11 (6.0) 6 (8.3)
Influenza B virus 4 (1.6) 0 (0.0) 4 (5.6)
Adenovirus 14 (5.5) 4 (2.2) 10 (13.9)
Bocavirus 1/2/3/4 9 (3.5) 0 (0.0) 9 (12.5)
Respiratory syncytial virus A 8 (3.1) 4 (2.2) 4 (5.6)
Respiratory syncytial virus B 6 (2.4) 5 (2.7) 1 (1.4)
Parainfluenza virus 1 1 (0.4) 1 (0.5) 0 (0.0)
Parainfluenza virus 2 1 (0.4) 0 (0.0) 1 (1.4)
Parainfluenza virus 3 6 (2.4) 3 (1.6) 3 (4.2)
Parainfluenza virus 4 5 (2.0) 2 (1.1) 3 (4.2)
Human Metapneumovirus 5 (2.0) 2 (1.1) 3 (4.2)
Enterovirus 3 (1.2) 0 (0.0) 3 (4.2)
Coronavirus 229E 1 (0.4) 1 (0.5) 0 (0.0)
Coronavirus NL63 2 (0.8) 1 (0.5) 1 (1.4)
Coronavirus OC43 1 (0.4) 1 (0.5) 0 (0.0)
Non respiratory viruses 3 (1.2) 3 (1.6) 0 (0.0)
Fungi, n (%) 10 (3.9) 9 (4.9) 1 (1.4)
Pneumocystis jirovecii 6 (2.4) 6 (3.3) 0 (0.0)
Other fungi 4 (1.6) 3 (1.6) 1 (1.4)
Pathogens associated with mixed infections were counted individually
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Fig. 1 Distribution of respiratory viruses detected as single or mixed pathogen
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were treated with antibiotics in 92% (p = 0.09) and longer
than those with a viral etiology or no pathogen (p = 0.02;
p = 0.01). If children and adults were analyzed individually,
similar but non-significant trends were observed (Tables 5,
6 and 7).
Influence of rtPCR testing on management
The effect of rtPCR analysis on antibiotic management
is presented in Tables 8, 9 and 10. After exclusion of pa-
tients who received antibiotics for other indications virus
detection was temporally associated with discontinuation
of antibiotics in 2 of 20 adults (10%) and 6 of 14 children
(43%). In patients with viral etiology, management was
more frequently judged correct in children (18/27, 67%)
than in adults (12/35, 34%; p = 0.01) after rtPCR resultsFig. 2 a Distribution of identified pathogens for adults. b Distribution of idbecame available. In adults, management of viral eti-
ology was less often judged correct compared to adults
with bacterial etiology (p = 0.002). Among patients with
clinically viral etiology, children were more frequently
managed correctly (15/15, 100%) than adults (8/13, 62%;
p = 0.03).
Eight adults and one child received oseltamivir. In four
of five patients with proven influenza A virus infection,
the antiviral medication was prescribed in response to
the positive rtPCR analysis. In another child, oseltamivir
was commenced after the third successive detection of
influenza A virus within a month and stopped after 1
day. In two other patients, antiviral therapy was started
or continued despite an rtPCR analysis negative for in-
fluenza and positive for other respiratory viruses. In an-
other patient with identification of only bacterialentified pathogens for children
Table 5 Outcome depending on relevant detected pathogen for adult patients
Viral Bacterial Mixed No pathogen p-valuea






LOS inpatients, median days (IQR) 8 (6–21) 21 (13–35) 11.5 (5–44.25) 15 (8–23.5) <0.001 0.67 0.03
Complications, n (%)
ICU admission 11 (27.5) 13 (36.1) 3 (50.0) 24 (24.0) 0.42 0.51 0.67
Mechanical ventilation 6 (15.0) 11 (30.6) 3 (50.0) 19 (19.0) 0.11 0.16 0.58
ARDS 3 (7.5) 5 (13.9) 2 (33.3) 6 (6.0) 0.60 0.24 1.00
Sepsis 24 (60.0) 24 (66.7) 5 (83.3) 6 (6.0)b 0.55 0.53 n/a
Mortality (all cause) 4 (10.0) 4 (11.1) 1 (16.7) 6 (6.0) 1.00 1.00 0.62
Antibiotic use (any indication)
Any inpatient antibiotics, n (%) 30/35 (85.7) 29/32 (90.6) 4/6 (66.7) 72/89 (80.9) 0.81 0.54 0.53
Duration of inpatient use,
mean days ± SD (range)
12.5 ± 14.3 (0–63) 18.1 ± 16.0 (0–72) 10.3 ± 12.1 (0–31) 10.8 ± 11.4 (0–63) 0.14 0.73 0.49
Discharged receiving oral
antibiotics, n (%)
11 (30.6)c 17 (53.1)d 1 (20.0)e 23 (24.5)f 0.06 1.00 0.48
ARDS acute respiratory distress syndrome, ICU intensive care unit, IQR interquartile range, LOS length of stay, n number, SD standard deviation
aFor continuous variables, 2-sample independent t-test or Mann-Whitney-U-test were used. For categorical variables, Mantel-Haenszel chi square or Fisher exact
test were used
bSepsis requires a pathogen per definition. In these six cases sepsis was exceptionally defined according to discharge papers
Missing values due to death or ongoing hospitalisation at time of analysis (number): c4; d4; e1; f6. For calculation of percentage and p-value missing values were excluded
Mayer et al. Pneumonia  (2017) 9:4 Page 9 of 16pathogens, oseltamivir was stopped after negative rtPCR
results were available. In an additional case with detec-
tion of bacteria only, antiviral medication was started 3
days after rtPCR analysis and it was stopped again on
the next day.Table 6 Outcome depending on relevant detected pathogen for pe
Viral Bacterial
(n = 40) (n = 6)
LOS inpatients, median days (IQR) 18.5 (6–48.75) 47.5 (14–95.75)
Complications, n (%)
ICU admission 18 (45.0) 4 (66.7)
Mechanical ventilation 8 (20.0) 4 (66.7)
ARDS 1 (2.5) 0 (0.0)
Sepsis 17 (42.5) 4 (66.7)
Mortality (all cause) 2 (5.0) 0 (0.0)
Antibiotic use (any indication)
Any inpatient antibiotics, n (%) 28/38 (73.7) 6/6 (100.0)
Duration of inpatient use,
mean days ± SD (range)
8.6 ± 13.4 (0–73) 14.2 ± 11.0 (0–34)
Discharged receiving oral
antibiotics, n (%)
6 (15.8)b 0 (0.0)
ARDS acute respiratory distress syndrome, ICU intensive care unit, IQR interquartile
aFor continuous variables, 2-sample independent t-test or Mann-Whitney-U-test we
test were used
Missing values due to death or ongoing hospitalisation at time of analysis (number
were excludedOutcomes depending on etiology
Hospital length of stay (LOS) was longer in patients with
bacterial etiology compared to patients with a viral eti-
ology. For children, LOS did not significantly vary in the
different groups between viral and bacterial etiologiesdiatric patients
Mixed No pathogen p-valuea






34 (17.5–201.5) 37 (8–70) 0.19 0.10 0.45
5 (100.0) 12 (57.1) 0.58 0.06 0.37
4 (80.0) 11 (52.4) 0.07 0.03 0.01
1 (20.0) 0 (0.0) 1.00 0.42 1.00
2 (40.0) 0 (0.0) 0.50 1.00 n/a
0 (0.0) 0 (0.0) 1.00 1.00 0.85
5/5 (100.0) 18/20 (90.0) 0.38 0.49 0.26
13.8 ± 7.8 (7–24) 6.2 ± 4.8 (0–18) 0.34 0.40 0.33
1 (20.0) 3 (15.0)c 0.78 1.00 1.00
range, LOS length of stay, n number, SD standard deviation
re used. For categorical variables, Mantel-Haenszel chi square or Fisher exact
): b2; c1. For calculation of percentage and p-value missing values
Table 7 Outcome depending on relevant detected pathogen for all patients
Viral Bacterial Mixed No pathogen p-valuea






LOS inpatients, median days (IQR) 12 (6–25.5) 22 (13–42.5) 27 (8–72) 16 (8–29.25) 0.004 0.20 0.20
Complications, n (%)
ICU admission 29 (36.3) 17 (40.5) 8 (72.7) 36 (29.8) 0.65 0.05 0.34
Mechanical ventilation 14 (17.5) 15 (35.7) 7 (63.6) 30 (24.8) 0.03 0.01 0.22
ARDS 4 (5.0) 5 (11.9) 3 (27.3) 6 (5.0) 0.31 0.07 1.00
Sepsis 41 (51.3) 28 (66.7) 7 (63.6) 6 (5.0)b 0.10 0.44 n/a
Mortality (all cause) 6 (7.5) 4 (9.5) 1 (9.1) 6 (5.0) 0.94 1.00 0.65
Antibiotic use (any indication)
Any inpatient antibiotics, n (%) 58/73 (79.5) 35/38 (92.1) 9/11 (81.8) 90/109 (82.6) 0.09 1.00 0.60
Duration of inpatient use,
mean days ± SD (range)
10.5 ± 13.9 (0-73) 17.5 ± 15.3 (0–72) 11.9 ± 10.0 (0–31) 10.0 ± 10.6 (0–63) 0.02 0.75 0.80
Discharged receiving oral
antibiotics, n (%)
17 (23.0)c 17 (44.7)d 2 (20.0)e 26 (22.8)f 0.02 1.00 0.98
ARDS acute respiratory distress syndrome, ICU intensive care unit, IQR interquartile range, LOS length of stay, n number, SD standard deviation
aFor continuous variables, 2-sample independent t-test or Mann-Whitney-U-test were used. For categorical variables, Mantel-Haenszel chi square or Fisher exact
test were used
bSepsis requires a pathogen per definition. In these six cases sepsis was exceptionally defined according to discharge papers
Missing values due to death or ongoing hospitalisation at time of analysis (number): c6; d4; e1; f7. For calculation of percentage and p-value missing values
were excluded
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more frequently admitted to the intensive care unit
(ICU) and mechanically ventilated compared to patients
with a viral etiology (p = 0.05; p = 0.005; respectively). If
children and adults were analyzed separately, the differ-
ences within the adult population were not significant;
in children, more patients with a mixed infection were
mechanically ventilated (p = 0.03). All-cause and RTI-
associated mortality was comparable between pathogen
groups.Table 8 Change of antibiotic therapy after rtPCR, adult patients with
Viral Bacterial Mixed No pathog
(n = 35) (n = 33) (n = 6) (n = 84)
No antibiotic treatment before
and after rtPCR, n (%)
10 (28.6) 7 (21.2) 2 (33.3) 32 (38.1)
Antibiotic treatment stopped
after rtPCR, n (%)
2 (5.7) 2 (6.1) 0 (0.0) 2 (2.4)
Antibiotic treatment started
after rtPCR, n (%)
5 (14.3) 4 (12.1) 2 (33.3) 8 (9.5)
Antibiotic treatment before
and after rtPCR, n (%)
18 (51.4) 20 (60.6) 2 (33.3) 42 (50.0)
Correct management, n (%) 12 (34.3) 24 (72.7) 4 (66.7)
n number; rtPCR, real-time polymerase chain reaction
aCases without detection of bacteria were evaluated as clinically bacterial if they fu
infiltrate or CRP >100 mg/l or PCT >0.25 μg/l or antibiotic therapy before rtPCR and
PCT ≤0.25 μg/l or CRP between 51 and 100 mg/l and PCT not available)
bCases with a detected viral pathogen excluding those patients with a clinically bac
cMantel-Haenszel chi square test or Fisher exact test were usedIn patients with viral etiology there was no difference
in mortality between those who discontinued antibiotics
compared to those who did not (1/8 [13%] vs. 3/26
[12%]; p = 1.00). LOS was shorter in inpatients who dis-
continued antibiotics (median days 5 [IQR 3–11.75] vs.
10.5 [IQR 6–19.25]; p = 0.05). Patients in whom antibiotics
were continued despite a viral detection were as frequently
admitted to ICU (11/26 [42%] vs. 5/8 [63%]; p = 0.55) or
mechanically ventilated (6/26 [23%] vs. 1/8 [13%]; p = 0.93)
as patients in whom antibiotics were discontinued. Theanother indication for antibiotics were excluded
en Clinically Clinically p-valuec






18 (21.4) 8 (61.5) 0.49 1.00 0.32
4 (4.8) 0 (0.0) 1.00 1.00 0.67
7 (8.3) 3 (23.1) 1.00 0.54 0.64
55 (65.5) 2 (15.4) 0.45 0.71 0.89
62 (73.8) 8 (61.5) 0.002 0.30 n/a
lfilled one of the following criteria: unilobular or multilobular pulmonary
no bacterium detection and biomarkers indeterminate (CRP >100 mg/l and
terial co-infection (as described above)
Table 9 Change of antibiotic therapy after rtPCR, pediatric patients with another indication for antibiotics were excluded
Viral Bacterial Mixed No pathogen Clinically Clinically p-valuec






No antibiotic treatment before
and after rtPCR, n (%)
12 (44.4) 1 (25.0) 0 (0.0) 6 (33.3) 6 (27.3) 11 (73.3) 0.87 0.40 0.46
Antibiotic treatment stopped
after rtPCR, n (%)
6 (22.2) 0 (0.0) 0 (0.0) 1 (5.6) 2 (9.1) 4 (26.7) 0.80 1.00 0.27
Antibiotic treatment started
after rtPCR, n (%)
1 (3.7) 0 (0.0) 1 (33.3) 3 (16.7) 3 (13.6) 0 (0.0) 1.00 0.39 0.34
Antibiotic treatment before
and after rtPCR, n (%)
8 (29.6) 3 (75.0) 2 (66.7) 8 (44.4) 11 (50.0) 0 (0.0) 0.23 0.50 0.32
Correct management, n (%) 18 (66.7) 3 (75.0) 3 (100.0) 14 (63.6) 15 (100.0) 1.00 0.66 n/a
n number; rtPCR, real-time polymerase chain reaction
aCases without detection of bacteria were evaluated as clinically bacterial if they fulfilled one of the following criteria: unilobular or multilobular pulmonary
infiltrate or CRP >100 mg/l or PCT >0.25 μg/l or antibiotic therapy before rtPCR and no bacterium detection and biomarkers indeterminate (CRP >100 mg/l and
PCT ≤0.25 μg/l or CRP between 51 and 100 mg/l and PCT not available)
bCases with a detected viral pathogen excluding those patients with a clinically bacterial co-infection (as described above)
cMantel-Haenszel chi square test or Fisher exact test were used
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[62%] vs. 6/8 [75%]; p = 0.80). These results were similar if
adults and children were analyzed separately.Radiological findings depending on etiology
Normal CXR findings were significantly more frequent
in patients with viral infection compared to bacterial in-
fections (30% vs. 9%; p = 0.03). Multilobar infiltrates and
pleural effusion on CXR were observed less often among
subjects with viral infection (Tables 11, 12 and 13).Predictors of viral etiology
In multivariate logistic regression (Tables 14 and 15), the
absence of pleural effusion in adults was associated with
detection of respiratory viruses (odds ratio [OR] 0.31, 95%
confidence interval [CI] 0.12–0.80). For children, the lackTable 10 Change of antibiotic therapy after rtPCR, all patients with
Viral Bacterial Mixed No pathoge
(n = 62) (n = 37) (n = 9) (n = 102)
No antibiotic treatment before
and after rtPCR, n (%)
22 (35.5) 8 (21.6) 2 (22.2) 38 (37.3)
Antibiotic treatment stopped
after rtPCR, n (%)
8 (12.9) 2 (5.4) 0 (0.0) 3 (2.9)
Antibiotic treatment started
after rtPCR, n (%)
6 (9.7) 4 (10.8) 3 (33.3) 11 (10.8)
Antibiotic treatment before
and after rtPCR, n (%)
26 (41.9) 23 (62.2) 4 (44.4) 50 (49.0)
Correct management, n (%) 30 (48.4) 27 (73.0) 7 (77.7)
n number; rtPCR, real-time polymerase chain reaction
aCases without detection of bacteria were evaluated as clinically bacterial if they fu
infiltrate or CRP >100 mg/l or PCT >0.25 μg/l or antibiotic therapy before rtPCR and
PCT ≤0.25 μg/l or CRP between 51 and 100 mg/l and PCT not available)
bCases with a detected viral pathogen excluding those patients with a clinically bac
cMantel-Haenszel chi square test or Fisher exact test were usedof multilobar infiltrates was a significant predictor of re-
spiratory virus detection (OR 0.22, 95% CI 0.06–0.81).
Discussion
There are three main findings in this retrospective co-
hort study of the impact of viral multiplex rtPCR. First,
the majority of patients with viral RTI received antibi-
otics and antibiotics were discontinued after viral detec-
tion in only a minority of patients. Second, when
biomarkers, radiologic presentations and antibiotic pre-
treatment were taken into account and categories of
clinically bacterial and clinically viral infections were
created (which more closely reflect clinical decision
making), the multiplex rtPCR showed a greater impact
and considerably improved correct management of clin-
ically viral infections, from 67 to 100% among children
and from 34 to 62% among adults. Third, the impact of
rtPCR testing seemed to be more accentuated inanother indication for antibiotics were excluded
n Clinically Clinically p-valuec






24 (22.6) 19 (67.9) 0.15 0.71 0.82
6 (5.7) 4 (14.3) 0.40 0.64 0.03
10 (9.4) 3 (10.7) 1.00 0.16 0.82
66 (62.3) 2 (7.1) 0.05 1.00 0.38
76 (71.7) 23 (82.1) 0.02 0.19 n/a
lfilled one of the following criteria: unilobular or multilobular pulmonary
no bacterium detection and biomarkers indeterminate (CRP >100 mg/l and
terial co-infection (as described above)
Table 11 Radiological findings for adult patients
Viral Bacterial Mixed No pathogen p-valuea
(n = 40) (n = 36) (n = 6) (n = 100) Viral vs. bacterial Viral vs. mixed Viral vs. no pathogen
X-ray, (n) 33 26 5 81
Unilobar infiltrate, n (%) 9 (27.3) 5 (19.2) 0 (0.0) 14 (17.3) 0.48 0.47 0.23
Multilobar infiltrates, n (%) 6 (18.2) 10 (38.5) 2 (40.0) 30 (37.0) 0.09 0.56 0.05
Interstitial infiltrates, n (%) 3 (9.1) 7 (26.9) 1 (20.0) 17 (21.0) 0.14 0.89 0.13
Pleural effusion, n (%) 5 (15.2) 11 (42.3) 0 (0.0) 24 (29.6) 0.02 0.95 0.11
Normal, n (%) 8 (24.2) 2 (7.7) 1 (20.0) 14 (17.3) 0.18 1.00 0.40
Computer tomography, (n) 23 29 5 71
Unilobar infiltrate, n (%) 5 (21.7) 4 (13.8) 0 (0.0) 7 (9.9) 0.70 0.69 0.26
Multilobar infiltrates, n (%) 11 (47.8) 16 (55.2) 4 (80.0) 32 (45.1) 0.60 0.42 0.82
Ground glass opacity, n (%) 4 (17.4) 6 (20.7) 2 (40.0) 29 (40.8) 1.00 0.57 0.04
Pleural effusion, n (%) 5 (21.7) 13 (44.8) 1 (20.0) 25 (35.2) 0.09 1.00 0.23
Normal, n (%) 2 (8.7) 0 (0.0) 0 (0.0) 0 (0.0) 0.38 1.00 0.12
n number. Multiple findings were counted individually
aMantel-Haenszel chi square test or Fisher exact test were used
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an appropriate discontinuation of antibiotics, and the
overall management of viral infections was superior in
children compared to adults. Importantly, but with the
caveat of small numbers, there was no evidence that out-
come was worse in those with viral etiology who discon-
tinued antibiotics compared to those who did not.
Several previous studies analyzed the impact of rapid
availability of rtPCR results on antibiotic use. In a ran-
domized controlled trial (RCT) of 107 adults with lower
RTI, antibiotics were partially or totally discontinued in
6 (11%) of 55 patients for whom rtPCR results were
available, albeit without overall reduction in antibioticTable 12 Radiological findings for pediatric patients
Viral Bacterial Mixed No
(n = 40) (n = 6) (n = 5) (n =
X-ray, (n) 28 6 5 16
Unilobar infiltrate, n (%) 6 (21.4) 0 (0.0) 1 (20.0) 2 (1
Multilobar infiltrates, n (%) 6 (21.4) 2 (33.3) 4 (80.0) 6 (3
Interstitial infiltrates, n (%) 2 (7.1) 1 (16.7) 1 (20.0) 2 (1
Pleural effusion, n (%) 4 (14.3) 2 (33.3) 1 (20.0) 2 (1
Normal, n (%) 10 (35.7) 1 (16.7) 0 (0.0) 3 (1
Computer tomography, (n) 5 1 2 3
Unilobar infiltrate, n (%) 2 (40.0) 0 (0.0) 0 (0.0) 0 (0
Multilobar infiltrates, n (%) 2 (40.0) 1 (100.0) 2 (100.0) 3 (1
Ground glass opacity, n (%) 0 (0.0) 0 (0.0) 1 (50.0) 0 (0
Pleural effusion, n (%) 2 (40.0) 1 (100.0) 1 (50.0) 2 (6
Normal, n (%) 1 (20.0) 0 (0.0) 0 (0.0) 0 (0
n number. Multiple findings were counted individually
aMantel-Haenszel chi square test or Fisher exact test were usedtreatment duration [7]. In a controlled clinical trial en-
rolling 583 children with acute RTI, Wishaupt et al. [4]
evaluated the diagnostic yield and effect of rapid commu-
nication of rtPCR results (within 12–36 h vs. 4 weeks after
testing) and failed to show a significant influence on the
duration of antibiotic treatment. In contrast, Brittain-Long
et al. [20] demonstrated in a RCT with 406 adults that
patients randomized to rapid rtPCR results received anti-
biotics less frequently for acute RTI in a primary care set-
ting during their initial visit (4.5% vs. 12.3%; p = 0.01).
However, at the 10-day follow-up the prescription rates
were similar again (13.9% vs. 17.2%; p = 0.36) [20]. Con-
trary to these findings, a retrospective pre-post study ofpathogen p-valuea
21) Viral vs. bacterial Viral vs. mixed Viral vs. no pathogen
2.5) 0.56 1.00 0.76
7.5) 0.88 0.04 0.42
2.5) 0.91 0.80 0.93
2.5) 0.56 1.00 1.00
8.8) 0.70 0.28 0.40
.0) 1.00 0.95 0.71
00.0) 1.00 0.57 0.36
.0) n/a 0.57 n/a
6.7) 1.00 1.00 1.00
.0) 1.00 1.00 1.00
Table 13 Radiological findings for all patients
Viral Bacterial Mixed No pathogen p-valuea
(n = 80) (n = 42) (n = 11) (n = 121) Viral vs. bacterial Viral vs. mixed Viral vs. no pathogen
X-ray, (n) 61 32 10 97
Unilobar infiltrate, n (%) 15 (24.6) 5 (15.6) 1 (10.0) 16 (16.5) 0.32 0.57 0.21
Multilobar infiltrates, n (%) 12 (19.7) 12 (37.5) 6 (60.0) 36 (37.1) 0.06 0.03 0.02
Interstitial infiltrates, n (%) 5 (8.2) 8 (25.0) 2 (20.0) 19 (19.6) 0.06 0.51 0.05
Pleural effusion, n (%) 9 (14.8) 13 (40.6) 1 (10.0) 26 (26.8) 0.01 1.00 0.08
Normal, n (%) 18 (29.5) 3 (9.4) 1 (10.0) 17 (17.5) 0.03 0.37 0.08
Computer tomography, (n) 28 30 7 74
Unilobar infiltrate, n (%) 7 (25.0) 4 (13.3) 0 (0.0) 7 (9.5) 0.26 0.35 0.10
Multilobar infiltrates, n (%) 13 (46.4) 17 (56.7) 6 (85.7) 35 (47.3) 0.44 0.14 0.94
Ground glass opacity, n (%) 4 (14.3) 6 (20.0) 3 (42.9) 29 (39.2) 0.82 0.25 0.02
Pleural effusion, n (%) 7 (25.0) 14 (46.7) 2 (28.6) 27 (36.5) 0.09 1.00 0.28
n number. Multiple findings were counted individually
aMantel-Haenszel chi square test or Fisher exact test were used
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panded multiplex rtPCR had a shorter turnaround time
and decreased the duration of antibiotic use (2.8 vs.
3.2 days; p = 0.003) without reducing the proportion of
antibiotic prescriptions [26].
As in most previous studies, typical respiratory bac-
teria were not included in the test panel. Due to this
technical limitation, missing a treatable pathogen is of
concern in light of potential bacterial-viral co-infections
[3, 7–13, 16–19]. It was shown that clinical suspicion of
a bacterial super-infection was one reason for physicians
to not stop antibiotics in rtPCR-positive patients [3]. We
tried to partially overcome this by creating categories of
clinically bacterial and clinically viral infections. This
definition, aided by providing a biomarker criterion,
accounted for the possibility of a viral infection in the
setting of bacterial carriage. One of the major differences
and advantages of the current study compared to previ-
ous publications is that it not only assessed the impact
of the rtPCR results, which themselves had a limited im-
pact on appropriate therapy, but it also integrated other
‘real-world’ clinical and radiologic parameters into the
decision process.Table 14 Prediction of respiratory virus detection for adult
patients
Univariable analysis Multivariable analysis
Predictor p-value OR (95% CI) p-value OR (95% CI)
Neutropenia 0.01 3.46 (1.32–9.07) 0.27 2.11 (0.56–7.89)
Hematologic
malignancy
0.04 2.25 (1.02–4.97) 0.59 1.35 (0.45–4.01)
Pleural effusion 0.02 0.36 (0.15–0.86) 0.02 0.31 (0.12–0.80)
Platelets
(minimum), G/l
0.02 1.00 (0.99–1.00) 0.20 1.00 (0.99–1.00)Advanced molecular diagnostic tests have to be inter-
preted in the context of available clinical and diagnostic
information in order to improve clinical management.
The results confirmed the important role of clinical
judgement for appropriate antibiotic prescriptions, with
rtPCR providing additional information rather than be-
ing solely responsible for treatment decisions.
Quantification of genomic viral load might improve
specificity of virus detection, with higher organism bur-
den being associated with higher risk of complications
and severe disease in adults and children [27, 28]. Unfor-
tunately, quantitative results were not available with the
applied assay. Similarly, optimal timing of molecular
testing in relation to symptom onset and inclusion of an
ever-expanding number of respiratory viruses might be
important to further increase sensitivity [27]. However,
to the authors’ knowledge, it has not yet been studied
whether either of these two factors would improve clin-
ical management.
A pathogen was identified in 140 (55%) patients in this
study, in accordance with detection rates in other studies
ranging from 38 to 82% [4, 12, 17, 19, 20, 22, 29–35]. A
mixed bacterial-viral etiology was found in 11 (8%)Table 15 Prediction of respiratory virus detection for pediatric
patients
Univariable analysis Multivariable analysis
Predictor p-value OR (95% CI) p-value OR (95% CI)
Neutropenia 0.06 7.75 (0.92–65.66) 0.10 7.44 (0.69–80.42)
Multilobular
infiltrates
0.03 0.31 (0.11–0.91) 0.02 0.22 (0.06–0.81)
White blood cells
(maximum), G/l
0.02 0.94 (0.89–0.99) 0.10 0.95 (0.90–1.01)
OR odds ratio, CI confidence interval
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23% [17, 19, 22, 29–35]. Some studies suggested that mixed
bacterial-viral infections result in more severe clinical dis-
eases (as measured by the CURB-65 score or the pneumo-
nia severity index) [17, 34], a higher rate of mechanical
ventilation, longer duration of ICU care [36, 37], longer
hospital stays [22, 36], or higher mortality [37, 38], while
other studies did not [29, 39, 40]. In this study, mixed
bacterial-viral infections were associated with a higher rate
of ICU admission and mechanical ventilation compared to
pure viral (p = 0.05; p = 0.005) and pure bacterial (p = 0.06;
p = 0.19) infections if all patients were considered. How-
ever, these results should not be viewed as representative
of the etiology of lower RTI in East Switzerland as these
hospitals presented a preselected group of patients.
In agreement with the findings of some studies [20,
22, 34] and in contrast to others [7, 29, 39], this study
failed to identify specific predictors of viral detection in
multivariate logistic regression. Advancing age was previ-
ously described as more common in viral infections [19,
22, 29, 35] but the evidence is inconclusive [31, 32]. In
this study, younger age was a significant predictor of
virus detection in univariable logistic regression if all
patients were considered, but not in stratified analyses
in children and adults. The mean age in the group with
respiratory viral infections was lower than in the
remaining patients (29 vs. 47 years; p < 0.001) but the
differences were not significant if stratified for children
and adults.
There are some limitations to the study. First, the change
of anti-infective management was retrospectively matched
with the date of the rtPCR analysis. Exact time specifica-
tions were not available, leaving room for potential inaccur-
acies. It is not known whether and to what extent these or
other factors contributed to the clinical decisions in start-
ing, stopping, or continuing antibiotic therapy. Due to the
retrospective nature of the study, it was not possible to con-
sider the clinical presentation in the analysis. Therefore, it
was difficult to reproduce the decision-making process and
the primary indication for antibiotic therapy. This is an
important limitation because clinical judgement remains
essential concerning the use of antibiotics [41]. Further-
more, data on the consequences of rtPCR results on anti-
biotic treatment are difficult to obtain in the ambulatory
setting, which explains the relatively small number of
enrolled outpatients. Prospective studies or ideally RCTs
will be necessary to confirm the findings.
Second, creating categories of clinically bacterial and
clinically viral etiology by means of biomarker, radiologic
presentations and antibiotic pre-treatment was done arbi-
trarily to reflect real-life decision-making. These theoretical
reflections were important to better understand the find-
ings; however, and as noted above, retrospectively the actual
decision-making process remained unclear.Third, the study included patients with upper and
lower respiratory tract infections and did not exclude
patients with antibiotic pre-treatment or significant
underlying pathologic conditions, which may have biased
the results but reflects clinical routine. Not having algo-
rithms in place when to perform rtPCR testing or how
to apply the results likewise mirrors the real-world
scenario.
Fourth, the study’s multiplex rtPCR only included re-
spiratory viruses. Newer generation assays additionally
cover atypical and typical bacteria and increase the detec-
tion of potential respiratory pathogens, albeit with yet un-
resolved specificity issues as these typical bacterial
pathogens might also represent carriage in the absence of
disease [42].
Fifth, the prevalence of RSV was underestimated in this
study. In the population of hospitalized children, rapid de-
tection tests for RSV were performed initially and, if posi-
tive, no additional rtPCR was performed. Because the study
included only patients in whom an rtPCR assay for respira-
tory viruses was performed, the number of RSV infections
was lower than expected from epidemiological data.
Conclusion
This study reveals the real-life impact of viral multiplex
rtPCR in both children and adults, which was more lim-
ited in adults but improved when results were seen in
the context of biomarkers, radiology, and antibiotic pre-
treatment. As substantial reduction of unnecessary anti-
biotic prescriptions seems possible, it will be necessary
to develop more structured management algorithms in-
corporating molecular diagnostics including bacterial
pathogens, which need to be prospectively tested in their
efficacy and safety in RTI.
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